The Emory Antibiotic Resistance Center

The Emory Antibiotic Resistance Center (ARC) unites a multidisciplinary group of researchers and clinicians with expertise in basic and translational science, epidemiology, and quality improvement to study and combat antibiotic resistance.

The ARC capitalizes on Emory’s collaborative environment, expertise, previous successes in translational research and drug development, and existing international partnerships, including the Queensland Emory Development Alliance.

The ARC’s goals are:
•    To understand how antibiotic-resistant bacteria cause disease and become refractory to antibiotics
•    To determine the causes of unexplained treatment failures
•    To pursue advanced molecular diagnostics for antibiotic-resistant microbes, particularly genome-based approaches
•    To integrate a scholarly and hypothesis-driven approach to antibiotic stewardship and the prevention of health care-associated infections
•    To develop novel drugs and vaccines to fight highly resistant bacteria

These goals are aligned with the highest priorities of the National Institutes of Health and the National Institute of Allergy and Infectious Diseases. Trainees supported by the Antimicrobial Resistance and Therapeutic Discovery Training Program (ARTDTP) are strongly encouraged to attend ARC activities to stay informed on new developments in the areas of antimicrobial resistance, therapeutic discovery, and clinical medicine.  

Learn more about the Emory Antibiotic Resistance Center.